144 related articles for article (PubMed ID: 37216403)
21. Exocrine and endocrine pancreatic function in 21 patients suffering from autoimmune pancreatitis before and after steroid treatment.
Frulloni L; Scattolini C; Katsotourchi AM; Amodio A; Gabbrielli A; Zamboni G; Benini L; Vantini I
Pancreatology; 2010; 10(2-3):129-33. PubMed ID: 20460944
[TBL] [Abstract][Full Text] [Related]
22. Isolated immune-related pancreatic exocrine insufficiency associated with pembrolizumab therapy.
Prasanna T; McNeil CM; Nielsen T; Parkin D
Immunotherapy; 2018 Mar; 10(3):171-175. PubMed ID: 29370723
[TBL] [Abstract][Full Text] [Related]
23. Infliximab for Steroid-Refractory Immune Checkpoint Inhibitor-Induced Acute Pancreatitis.
Townsend MJ; Hodi FS; Grover S
ACG Case Rep J; 2023 Mar; 10(3):e01018. PubMed ID: 36998343
[TBL] [Abstract][Full Text] [Related]
24. Pancreatic adverse events of immune checkpoint inhibitors therapy for solid cancer patients: a systematic review and meta-analysis.
Zhao Z; Zhang W; Pang L; Zeng L; Liu S; Liu J
Front Immunol; 2023; 14():1166299. PubMed ID: 37359551
[TBL] [Abstract][Full Text] [Related]
25. Autoimmune Pancreatitis: From Pathogenesis to Treatment.
Nista EC; De Lucia SS; Manilla V; Schepis T; Pellegrino A; Ojetti V; Pignataro G; Zileri Dal Verme L; Franceschi F; Gasbarrini A; Candelli M
Int J Mol Sci; 2022 Oct; 23(20):. PubMed ID: 36293522
[TBL] [Abstract][Full Text] [Related]
26. Case Report: Nivolumab-Induced Autoimmune Pancreatitis.
Goyal P; Moyers JT; Elgohary BG; Hammami MB
J Immunother Precis Oncol; 2021 Nov; 4(4):208-211. PubMed ID: 35665025
[TBL] [Abstract][Full Text] [Related]
27. Risk factors and treatment of relapses in autoimmune pancreatitis: Rituximab is safe and effective.
Soliman H; Vullierme MP; Maire F; Hentic O; Ruszniewski P; Lévy P; Rebours V
United European Gastroenterol J; 2019 Oct; 7(8):1073-1083. PubMed ID: 31662864
[TBL] [Abstract][Full Text] [Related]
28. Management of immune-related hepatitis in patients being treated with checkpoint inhibitors for metastatic melanoma, a review and case series.
Tew A; Khoja L; Pallan L; Steven N
J Oncol Pharm Pract; 2023 Jul; 29(5):1163-1171. PubMed ID: 35607278
[TBL] [Abstract][Full Text] [Related]
29. Hepatobiliary Adverse Events.
Abu-Sbeih H; Wang Y
Adv Exp Med Biol; 2020; 1244():271-276. PubMed ID: 32301021
[TBL] [Abstract][Full Text] [Related]
30. Steroid Therapy and Steroid Response in Autoimmune Pancreatitis.
Matsubayashi H; Ishiwatari H; Imai K; Kishida Y; Ito S; Hotta K; Yabuuchi Y; Yoshida M; Kakushima N; Takizawa K; Kawata N; Ono H
Int J Mol Sci; 2019 Dec; 21(1):. PubMed ID: 31905944
[TBL] [Abstract][Full Text] [Related]
31. Immune checkpoint inhibitor-induced pure red cell aplasia: Case series and large-scale pharmacovigilance analysis.
Guo Q; Gao J; Guo H; Xie J; Cheng J
Int Immunopharmacol; 2023 Jan; 114():109490. PubMed ID: 36459923
[TBL] [Abstract][Full Text] [Related]
32. IgG4-related autoimmune pancreatitis-like mass-forming lesion on a background of immune checkpoint inhibitor immunotherapy.
Champion B; Chai SM; Bhandari M; Gunawardena D
Pathology; 2023 Feb; 55(1):133-136. PubMed ID: 35842321
[No Abstract] [Full Text] [Related]
33. Relapse rate and predictors of relapse in a large single center cohort of type 1 autoimmune pancreatitis: long-term follow-up results after steroid therapy with short-duration maintenance treatment.
Lee HW; Moon SH; Kim MH; Cho DH; Jun JH; Nam K; Song TJ; Park DH; Lee SS; Seo DW; Lee SK
J Gastroenterol; 2018 Aug; 53(8):967-977. PubMed ID: 29362937
[TBL] [Abstract][Full Text] [Related]
34. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
Cochrane Database Syst Rev; 2021 Apr; 4(4):CD013257. PubMed ID: 33930176
[TBL] [Abstract][Full Text] [Related]
35. [Immune-Related Pancreatitis Caused by Immune Checkpoint Inhibitor Nivolumab:Report of One Case].
Xu F; Shen Z; Tao H; Zhu Z; Tao JL; Feng ZY
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2023 Apr; 45(2):351-354. PubMed ID: 37157088
[TBL] [Abstract][Full Text] [Related]
36. Coexistence of Immune Checkpoint Inhibitor-Induced Autoimmune Diabetes and Pancreatitis.
Zhang AL; Wang F; Chang LS; McDonnell ME; Min L
Front Endocrinol (Lausanne); 2021; 12():620522. PubMed ID: 33927691
[TBL] [Abstract][Full Text] [Related]
37. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013257. PubMed ID: 33316104
[TBL] [Abstract][Full Text] [Related]
38. Immune Checkpoint Inhibitor-Associated Primary Adrenal Insufficiency: WHO VigiBase Report Analysis.
Grouthier V; Lebrun-Vignes B; Moey M; Johnson DB; Moslehi JJ; Salem JE; Bachelot A
Oncologist; 2020 Aug; 25(8):696-701. PubMed ID: 32390168
[TBL] [Abstract][Full Text] [Related]
39. Relationship between the exocrine and endocrine pancreas after acute pancreatitis.
Das SL; Kennedy JI; Murphy R; Phillips AR; Windsor JA; Petrov MS
World J Gastroenterol; 2014 Dec; 20(45):17196-205. PubMed ID: 25493036
[TBL] [Abstract][Full Text] [Related]
40. Diagnosis, treatment and long-term outcome of autoimmune pancreatitis in Sweden.
Vujasinovic M; Valente R; Maier P; von Beckerath V; Haas SL; Arnelo U; Del Chiaro M; Kartalis N; Pozzi-Mucelli RM; Fernandez-Moro C; Verbeke CS; Yu J; Ye W; Löhr JM
Pancreatology; 2018 Dec; 18(8):900-904. PubMed ID: 30236651
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
